Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2023
Reporting Period: Event-specific (November 16, 2023)
This filing discloses a regulatory disclosure event regarding a presentation by Dr. David Young, President of Research and Development, at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the announcement of a conference presentation.
Guidance, Outlook, and Management Commentary
- Event Details: Dr. David Young presented "Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial" on November 16, 2023, at 2:40 PM ET in Boston.
- Availability: The presentation is available as Exhibit 99.1 and on the company's website under the "Presentation" section.
- Forward-Looking Statements: The company undertakes no duty to update or revise the information contained in this report, though it may do so through future filings or press releases.
- Regulation FD: The company notes it routinely uses its website to disclose material non-public information.
Investor Verification Checklist
- Verify the content of the presentation titled "Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial" via Exhibit 99.1 or the company website.
- Confirm the company's status as an emerging growth company (indicated as not applicable in this filing).
- Review the company's website for any subsequent updates or revisions to the information presented at the conference.